Drugs in the Pipeline
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Drugs in the Pipeline, News
The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.
Drugs in the Pipeline, News
The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.
Drugs in the Pipeline
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
Drugs in the Pipeline
The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.
Drugs in the Pipeline
Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.
Drugs in the Pipeline
Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
Drugs in the Pipeline
The ACTT-2 study began on May 8 and included more than 1000 patients.
Drugs in the Pipeline
Lenzilumab is an investigational anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
Drugs in the Pipeline
Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.
